ICU Map

Massive Hemorrhage & Hemostatic Resuscitation

From emergent massive-hemorrhage protocol activation and early balanced component resuscitation to physiologic correction, targeted factor/anticoagulant reversal, and definitive source control.

RecognizeAssessDecideDifferentialInterveneReassess
Massive Hemorrhage / Exsanguinating Trauma / Severe GI Bleeding
Clinical ActionActivate Massive Transfusion Protocol (MTP) immediatelyExplore Topic
Criteria: hemodynamic instability with active severe hemorrhage, anticipated transfusion >4 PRBC units in 1h or >10 units in 24h. Notify blood bank and establish blood-warmer rapid infusor.
Clinical ActionDeliver early balanced component resuscitation using the local massive-hemorrhage protocol
Prevents dilutional coagulopathy and thrombocytopenia. Administer 1 adult dose of platelets for every 4–6 units of PRBCs and FFPs.
Clinical ActionAdminister Tranexamic Acid (TXA 1 g IV bolus over 10 min, then 1 g over 8h)
Give as early as possible within 3 hours of bleeding onset (CRASH-2 trial demonstrated significant mortality reduction).
Differential Branches (2)
1Branch
Decision PointSimultaneously correct the 'Lethal Triad' & reverse specific anticoagulants
Target: Temperature > 36°C (forced-air warmer/fluids), pH > 7.20, Ionized Calcium > 1.1 mmol/L (give 1 g IV calcium chloride per 4 units blood to counter citrate).
Clinical ActionDOAC / Warfarin / Heparin Reversal
Warfarin: 4F-PCC + IV vitamin K. Dabigatran: idarucizumab 5 g. Apixaban/rivaroxaban: use the locally supported factor-Xa reversal strategy (commonly 4F-PCC in current U.S. practice; andexanet is discontinued in the U.S. as of 2026). Heparin: protamine sulfate. Use institutional dosing protocols because PCC dose strategies vary by indication and product.
Clinical ActionPursue definitive endoscopic / surgical / interventional source control
Endoscopy for GI bleed, surgical packing/hemostasis, or interventional radiology angioembolization.
2Branch
Reassessment / LoopGuide targeted replacement with TEG/ROTEM & de-escalate MTPExplore Topic
Target: Fibrinogen > 1.5–2.0 g/L (give Cryoprecipitate if low), Platelets > 50,000 (100,000 in neurotrauma), INR < 1.5. De-escalate MTP once surgical hemostasis is verified.

An educational representation of clinical reasoning, not a diagnostic algorithm or personalized medical advice — always apply clinical judgment and institutional protocols.

Caution

Escalate — Red Flags & Critical Warnings

  • Severe hypocalcemia during rapid massive transfusion — ionized calcium falls precipitously as citrate binds calcium, causing electromechanical dissociation and profound myocardial depression; replace 1 g IV calcium chloride every 4 blood units.
  • Hyperkalemic cardiac arrest during rapid transfusion of stored PRBC units in acidotic/hypotensive patients — monitor potassium continuously and have calcium chloride and shifting agents ready.

Related Bedside Clinical Problems (20)

Bedside Presentations
New or Massive Hemoptysis

Airway preservation and bleeding localization: non-massive vs massive hemoptysis (> 100–200 mL/hr), lateral decubitus positioning, isolation of the bleeding lung, and endovascular/bronchoscopic intervention.

View Bedside Problem →
Acute Hypotension & Undifferentiated Shock

Rapid bedside hemodynamic categorization: confirming MAP < 65 mmHg, assessing peripheral perfusion, POCUS cardiac/IVC profiling, and differentiating hypovolemic, distributive, cardiogenic, and obstructive etiologies.

View Bedside Problem →
Refractory Shock Despite High-Dose Vasopressors

Advanced multimodal hemodynamic rescue: second-line vasopressors (vasopressin, angiotensin II), inotropic augmentation, stress-dose steroids, metabolic correction, and mechanical circulatory support evaluation.

View Bedside Problem →

Linked Deep-Dive Topics (8)

Reference Knowledge
Major Bleeding, Hemorrhagic Shock, & Damage Control Resuscitationhematology

The trauma lethal diamond (hypothermia, acidosis, coagulopathy, hypocalcemia), 1:1:1 massive transfusion (PROPPR trial), early TXA (CRASH-2), and TEG/ROTEM algorithms.

Explore Topic →
Blood Product Transfusion in Critical Carehematology

Patient-specific RBC transfusion thresholds, current platelet/procedural thresholds, plasma/cryoprecipitate use, and the TRALI vs TACO diagnostic matrix.

Explore Topic →
Therapeutic Anticoagulation & Emergency Reversal in the ICUhematology

UFH vs LMWH vs DTIs (Argatroban/Bivalirudin), anti-Xa vs aPTT monitoring, and emergency reversal (Protamine, 4F-PCC, Idarucizumab; historical andexanet evidence with current availability caveats).

Explore Topic →
Disseminated Intravascular Coagulation (DIC) & Sepsis Coagulopathyhematology

Tissue-factor-driven coagulation activation, antithrombin/protein C depletion, PAI-1-associated fibrinolytic suppression, ISTH 2025 DIC assessment, comparison with TTP/HUS/HIT, and targeted replacement.

Explore Topic →
Upper Gastrointestinal Bleeding (UGIB)gi-hepatic

Risk-stratified non-variceal and variceal hemorrhage care: resuscitation, selective airway protection, individualized transfusion, PPI or portal-pressure therapy, endoscopic hemostasis, and escalation to IR/TIPS/surgery when indicated.

Explore Topic →
Lower Gastrointestinal Bleeding (LGIB)gi-hepatic

Risk stratification, selective assessment for an upper source, CTA localization of ongoing severe bleeding, endoscopic or catheter therapy, and individualized transfusion/resuscitation.

Explore Topic →
Shock: Foundational Critical Care Frameworkcardiovascular

Cellular dysoxia, DO2/VO2 physiology, the 4 shock phenotypes, dynamic fluid responsiveness (PLR/PPV) vs fluid tolerance (VExUS), and vasoactive pharmacology.

Explore Topic →
Heparin-Induced Thrombocytopenia (HIT)hematology

PF4-heparin antibody Fc-gamma-RIIa platelet activation, the 4Ts score, ELISA OD values vs Serotonin Release Assay (SRA), and direct thrombin inhibitor protocols.

Explore Topic →

Evidence status

Review metadata not yet recorded.

Status, review dates and guideline versions appear here once editorial metadata is authored for this content.